Tagged with GSK

Global The Access to Medicine Index, a biennial report that gauges the efforts of the world’s largest pharma companies to expand access in low- and middle-income countries (LMICs), found in this year’s edition that the 20 companies surveyed have firmly responded to access issues exposed by COVID-19. GSK remains at the…

Brazil After a successful international career, Andre Vivan da Silva recently returned to his native Brazil to become GSK’s country manager. He explains the importance of vaccination, in Brazil, and HIV in a country where GSK’s products treat at least half of its HIV patients. He also speaks about the company’s…

Global Fortune’s new 50 Most Powerful Women in Business list features four representatives of Big Pharma, as well as a further four from powerful US health insurance corporations.   The annual ranking is based on five criteria: the size and importance of a leader’s business in the global economy, the health…

Egypt Mohamed Ali Abd El Azim gives several insights into GSK’s sizeable production footprint in Egypt, how the organisation’s aims dovetail with Egypt’s healthcare transformation, and what makes him proud to work in pharma manufacturing.   Our country is improving and reshaping the healthcare industry and we as GSK have the…

Americas Two Big Pharma SVPs with responsibility for the entirety of Latin America weigh in on the management challenges inherent in LatAm and what they look for when appointing country managers in their region.   LatAm’s regional pharma market of USD 98 billion looks set to be the fastest growing in…

LatAm GSK’s head of Emerging Markets, Luis Arosemena, comments on the strategic importance of this wide-ranging country grouping for the company, the structure of his organisation in Latin America, the importance of the country manager role, and explains how strong institutions make up for volatility in Latin America.   Five of…

Global COVID-19 vaccines and treatments continue to make headline news and bring in huge revenues for sponsor companies, but Pharma Exec’s 2022 Top 50 Companies ranking suggests that many non-COVID products are once more driving big gains. Against the backdrop of an increasingly fraught geopolitical climate and patent landscape, the next…

Middle East & Africa Approaching two years in her position as GSK’s Vice President and General Manager for the Gulf region, Gizem Akalin, PhD, outlines the tremendous growth potential of her region, draws on her digital marketing expertise to reflect on the future of commercial teams post-COVID, and highlights why the UAE should become…

Global Pharma companies no longer view digital as a “nice to have” add on, but as an integral part of their business, yet there are still quite a few hurdles to overcome. Insights from pharma industry digital transformation leaders. Industry is on a dedicated and focused journey to leverage data and…

Canada Some of the top stories coming out of Canadian healthcare and life sciences, including a new GSK flu vaccine deal, Amylyx Pharmaceuticals’ first approval for an ALS drug, and the Public Health Agency of Canada’s recent smallpox contracts with Chimerix and Bavarian Nordic.   GSK flu vaccine deal renewal (Reuters)…

Global GSK has separated itself from its consumer healthcare business, newly named Haleon, home to brands such as Sensodyne and Advil. Now what? After underperforming in recent years, a few clinical trials fails and a resulting push for change from its investors, the breakup with its consumer healthcare arm was long-announced…

Italy Stanislao Caputo, GM at Aristo Pharma Italy, explains the Italian subsidiary’s strategy and how the diversification of its core business led to the acquisition of a portfolio of GSK dermo-cosmetic products. Aristo differentiates itself in the market through its dynamism and its ability to move quickly and diversify its business…